Varenicline and bupropion sustained-release combination therapy for smoking cessation

Jon Owen Ebbert, Ivana T Croghan, Amit Sood, Darrell R. Schroeder, James Taylor Hays, Richard D. Hurt

Research output: Contribution to journalArticle

78 Citations (Scopus)

Abstract

Introduction: Varenicline and bupropion sustained release (SR) are both safe and effective for the treatment of tobacco dependence and have different mechanisms of action. Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy. Methods: We enrolled cigarettes smokers in an open-label, one-arm, Phase II clinical trial to obtain preliminary data on the potential effectiveness and safety of combination therapy with varenicline and bupropion SR for the treatment of tobacco dependence. Eligible subjects received varenicline titrated to 1.0 mg by mouth twice daily and bupropion SR titrated to 150 mg by mouth twice daily for a total of 12 weeks along with behavioral therapy. Self-reported smoking abstinence was biochemically confirmed with expired carbon monoxide. A total of 38 smokers with a mean age of 49.1 years (SD = 12.4) who smoked an average of 19.9 cigarettes/day (SD = 7.8) for 30 years (SD = 12.3) were enrolled. Results: Seven-day point-prevalent smoking abstinence rates were 71% (95% CI = 54%-85%) at 3 months and 58% (95% CI = 41%-74%) at 6 months. Mean weight change during the medication phase among smoking-abstinent subjects was 1.6 kg (SD = 2.4). For both medications, 74% of subjects took at least 90% of the prescribed doses. The most common side effects were sleep disturbance (26%) and nausea (24%). No increase in depressive symptoms was observed, and no subjects reported suicidal ideation. Discussion: Combination therapy with varenicline and bupropion SR may be effective for increasing smoking abstinence rates above that observed with monotherapy.

Original languageEnglish (US)
Pages (from-to)234-239
Number of pages6
JournalNicotine and Tobacco Research
Volume11
Issue number3
DOIs
StatePublished - 2009

Fingerprint

Bupropion
Smoking Cessation
Smoking
Tobacco Use Disorder
Tobacco Products
Mouth
Therapeutics
Suicidal Ideation
Phase II Clinical Trials
Carbon Monoxide
Nausea
Varenicline
Sleep
Arm
Depression
Safety
Weights and Measures
Drug Therapy

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Varenicline and bupropion sustained-release combination therapy for smoking cessation. / Ebbert, Jon Owen; Croghan, Ivana T; Sood, Amit; Schroeder, Darrell R.; Hays, James Taylor; Hurt, Richard D.

In: Nicotine and Tobacco Research, Vol. 11, No. 3, 2009, p. 234-239.

Research output: Contribution to journalArticle

@article{ff0339da20ad4018a4e0a95fc1fecd5f,
title = "Varenicline and bupropion sustained-release combination therapy for smoking cessation",
abstract = "Introduction: Varenicline and bupropion sustained release (SR) are both safe and effective for the treatment of tobacco dependence and have different mechanisms of action. Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy. Methods: We enrolled cigarettes smokers in an open-label, one-arm, Phase II clinical trial to obtain preliminary data on the potential effectiveness and safety of combination therapy with varenicline and bupropion SR for the treatment of tobacco dependence. Eligible subjects received varenicline titrated to 1.0 mg by mouth twice daily and bupropion SR titrated to 150 mg by mouth twice daily for a total of 12 weeks along with behavioral therapy. Self-reported smoking abstinence was biochemically confirmed with expired carbon monoxide. A total of 38 smokers with a mean age of 49.1 years (SD = 12.4) who smoked an average of 19.9 cigarettes/day (SD = 7.8) for 30 years (SD = 12.3) were enrolled. Results: Seven-day point-prevalent smoking abstinence rates were 71{\%} (95{\%} CI = 54{\%}-85{\%}) at 3 months and 58{\%} (95{\%} CI = 41{\%}-74{\%}) at 6 months. Mean weight change during the medication phase among smoking-abstinent subjects was 1.6 kg (SD = 2.4). For both medications, 74{\%} of subjects took at least 90{\%} of the prescribed doses. The most common side effects were sleep disturbance (26{\%}) and nausea (24{\%}). No increase in depressive symptoms was observed, and no subjects reported suicidal ideation. Discussion: Combination therapy with varenicline and bupropion SR may be effective for increasing smoking abstinence rates above that observed with monotherapy.",
author = "Ebbert, {Jon Owen} and Croghan, {Ivana T} and Amit Sood and Schroeder, {Darrell R.} and Hays, {James Taylor} and Hurt, {Richard D.}",
year = "2009",
doi = "10.1093/ntr/ntn031",
language = "English (US)",
volume = "11",
pages = "234--239",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Varenicline and bupropion sustained-release combination therapy for smoking cessation

AU - Ebbert, Jon Owen

AU - Croghan, Ivana T

AU - Sood, Amit

AU - Schroeder, Darrell R.

AU - Hays, James Taylor

AU - Hurt, Richard D.

PY - 2009

Y1 - 2009

N2 - Introduction: Varenicline and bupropion sustained release (SR) are both safe and effective for the treatment of tobacco dependence and have different mechanisms of action. Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy. Methods: We enrolled cigarettes smokers in an open-label, one-arm, Phase II clinical trial to obtain preliminary data on the potential effectiveness and safety of combination therapy with varenicline and bupropion SR for the treatment of tobacco dependence. Eligible subjects received varenicline titrated to 1.0 mg by mouth twice daily and bupropion SR titrated to 150 mg by mouth twice daily for a total of 12 weeks along with behavioral therapy. Self-reported smoking abstinence was biochemically confirmed with expired carbon monoxide. A total of 38 smokers with a mean age of 49.1 years (SD = 12.4) who smoked an average of 19.9 cigarettes/day (SD = 7.8) for 30 years (SD = 12.3) were enrolled. Results: Seven-day point-prevalent smoking abstinence rates were 71% (95% CI = 54%-85%) at 3 months and 58% (95% CI = 41%-74%) at 6 months. Mean weight change during the medication phase among smoking-abstinent subjects was 1.6 kg (SD = 2.4). For both medications, 74% of subjects took at least 90% of the prescribed doses. The most common side effects were sleep disturbance (26%) and nausea (24%). No increase in depressive symptoms was observed, and no subjects reported suicidal ideation. Discussion: Combination therapy with varenicline and bupropion SR may be effective for increasing smoking abstinence rates above that observed with monotherapy.

AB - Introduction: Varenicline and bupropion sustained release (SR) are both safe and effective for the treatment of tobacco dependence and have different mechanisms of action. Combination pharmacotherapy with these agents may increase long-term smoking abstinence rates above what is observed with single-agent therapy. Methods: We enrolled cigarettes smokers in an open-label, one-arm, Phase II clinical trial to obtain preliminary data on the potential effectiveness and safety of combination therapy with varenicline and bupropion SR for the treatment of tobacco dependence. Eligible subjects received varenicline titrated to 1.0 mg by mouth twice daily and bupropion SR titrated to 150 mg by mouth twice daily for a total of 12 weeks along with behavioral therapy. Self-reported smoking abstinence was biochemically confirmed with expired carbon monoxide. A total of 38 smokers with a mean age of 49.1 years (SD = 12.4) who smoked an average of 19.9 cigarettes/day (SD = 7.8) for 30 years (SD = 12.3) were enrolled. Results: Seven-day point-prevalent smoking abstinence rates were 71% (95% CI = 54%-85%) at 3 months and 58% (95% CI = 41%-74%) at 6 months. Mean weight change during the medication phase among smoking-abstinent subjects was 1.6 kg (SD = 2.4). For both medications, 74% of subjects took at least 90% of the prescribed doses. The most common side effects were sleep disturbance (26%) and nausea (24%). No increase in depressive symptoms was observed, and no subjects reported suicidal ideation. Discussion: Combination therapy with varenicline and bupropion SR may be effective for increasing smoking abstinence rates above that observed with monotherapy.

UR - http://www.scopus.com/inward/record.url?scp=64949115403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64949115403&partnerID=8YFLogxK

U2 - 10.1093/ntr/ntn031

DO - 10.1093/ntr/ntn031

M3 - Article

C2 - 19246427

AN - SCOPUS:64949115403

VL - 11

SP - 234

EP - 239

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 3

ER -